Dyslipidemia

CagriSema, a fixed dose of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved statistically significant weight loss after 68 weeks versus placebo.

Olezarsen ushers in a new era of care as the first therapy to receive FDA approval for adults with familial chylomicronemia syndrome as an adjunct to diet.

Submission of the Biologics License Application seeks approval of lerodalcibep to lower LDL-C in patients with or at risk for ASCVD and primary hyperlipidemia.

Our Cardiology Month in Review for November 2024 spotlights the approval of acoramidis and top content from AHA 2024.

Muvalaplin, an oral treatment, reduced Lp(a) by up to 85% in a 12-week Phase 2 trial presented at AHA 2024.

Zerlasiran reduced Lp(a) by over 90% at 60 weeks with consistent efficacy and no serious drug-related adverse events, supporting its phase 3 trial progression.

A 6-year longitudinal study, involving more than 200,000 adults, reported a notable rise in dyslipidemia incidence during the COVID-19 pandemic.

A study found that adding depression to Life's Essential 8 provides minimal improvements in predicting cardiovascular and all-cause mortality risk.

A new meta-analysis found elevated triglyceride levels in patients with major depressive disorder, potentially explaining the link between depression and cardiovascular risks.

A new AHA statement highlights the benefits of lipoprotein apheresis for familial hypercholesterolemia and urges broader access to the underutilized therapy.

Time-restricted eating, even without calorie restriction, improved glycemic control and cardiometabolic health in patients with metabolic syndrome.

Rahul Aggarwal, MD, discusses how the VICTORION-1 PREVENT trial eligibility criteria apply to the general US population.

The HCPLive Cardiology month in review for September 2024 spotlights ESC Congress 2024, Family Heart Global Summit, pipeline updates, and more!

Elucid has received 510(k) clearance for its PlaqueIQ™ imaging analysis software to help physicians diagnose cardiovascular disease.

Subclinical atherosclerosis burden and its progression are independently linked to the risk of death from any cause in asymptomatic individuals.

Family Heart Foundation announces the launch of Cholesterol Connect, a program that provides free at-home lipid screening and personalized support.

A comparison of the PALISADE and BALANCE trials, with commentary from a leading cardiologist, as the community nears a potential approval in FCS.

Expert clinical consensus from the National Lipid Association finds ApoB testing is useful to stratify ASCVD risk more accurately than LDL-C.

The approval to GE Healthcare's cyclotron-produced radioactive diagnostic drug provides another option to adequately identify significant coronary artery disease.

Christie Ballantyne, MD, discusses non-statin therapies, both approved and in development, for managing dyslipidemias from the floor of the 2024 Family Heart Global Summit.

Elias discusses the challenges of prosthetic valve evaluation, highlighting the role of sonographers, Doppler imaging, and the importance of ongoing training.

A randomized trial suggests gefarnate significantly reduces triglycerides and LDL-C in older adults on statins with residual hypertriglyceridemia.

The joint guidelines address evidence on the management of patients before, during, and after noncardiac surgery since the last update in 2014.

Announced on September 24, 2024, the approval marks the second treatment approved by the FDA for Niemann-Pick disease type C within one week.

A Q&A with Nihar Desai, MD, on the PROMPT-Lipid trial and the potential of advancing technology for improving patient care in pragmatic ways.

Benjamin Scirica, MD, discusses the importance of team-based care and leveraging technology to optimize the management of cardiovascular risk factors.

Nihar Desai, MD, discusses the results of the PROMPT-Lipid trial while on-site at the 2024 Family Heart Global Summit.

Laurence Sperling, MD, discusses his presentation from the 2024 Family Heart Global Summit examining public health efforts for prevention of cardiovascular disease.

Arimoclomol, in combination with miglustat, is approved to treat neurological symptoms associated with NPC in adults and children aged ≥2 years.

Lp(a) ordering remains low in patients at risk for ASCVD, particularly non-Hispanic Black or Hispanic individuals in socioeconomically disadvantaged neighborhoods.